The U.S. Food and Drug Administration issued its first formal guidance on how to design and run clinical trials for ...

See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the near-term setup.

George Goldsmith is the Chairman, CEO and Co‑Founder of COMPASS Pathways (NASDAQ:CMPS). Mr. Goldsmith’s early training and experience was a multi-disciplinary blending of cognitive psychology, ...

Rarely do investors have the opportunity to invest in a pharmaceutical company doing clinical trials where the drug awaiting regulatory approval has been in use for decades. The US government has ...